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Summary 
Neutrophils are indispensable antagonists of microbial infection and facilitators of wound 
healing. In the cancer setting, a newfound appreciation for neutrophils has come into view. 
The traditionally held belief that neutrophils are inert bystanders is being challenged by 
recent literature. Emerging evidence indicates that tumors manipulate neutrophils, 
sometimes early in their differentiation process, to create diverse phenotypic and functional 
polarization states able to alter tumor behavior. In this Review, we discuss the involvement of 
neutrophils in cancer initiation and progression, and their potential as clinical biomarkers and 
therapeutic targets. 
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The name neutrophil – given to polymorphonuclear, granulocytic cells by Paul Ehrlich in the 
late 19th century – is based on the inability of these cells to retain acidic or basic dyes and 
for their preferential uptake of pH neutral dyes1. Although their neutral staining led to the 
identification of these cells, neutrophils in the cancer setting are anything but neutral. 
Neutrophils in tumor-bearing hosts can oppose or potentiate cancer progression. These two 
types of behavior are controlled by signals emanating from cancer cells or stromal cells 
within the tumor microenvironment, which educate neutrophils to execute the demise of the 
tumor or facilitate support networks that lead to its expansive spread. These functions can 
occur locally in or around the tumor microenvironment, as well as systemically in distant 
organs.  
Until the past few years, other immune cells such as macrophages have 
overshadowed the role of neutrophils in cancer. But recent studies and the development of 
new genetic tools have provided the cancer community with new insights into the profound 
influence of these dynamic cells by uncovering distinct capabilities for neutrophils throughout 
each step of carcinogenesis: from tumor initiation to primary tumor growth to metastasis. 
During these processes, neutrophils take on different phenotypes and sometimes opposing 
functions. Emerging evidence also indicates that these cells are highly influential, and are 
able to change the behavior of other tumor-associated cell types – primarily other immune 
cells. In this Review, we focus on how tumors manipulate the generation and release of 
neutrophils from the bone marrow. We discuss the mechanisms identified in animal models 
by which neutrophils participate in tumor initiation, growth and metastasis. Finally, we 
highlight the potential of these cells as clinical biomarkers and therapeutic targets. 
 
Neutrophil origins and life cycle: homeostasis versus cancer [Au: subheading too 
long, please shorten to <39 characters; possibly ‘Homeostasis versus cancer’ would 
work?] 
In humans, neutrophils are the most abundant immune cell population, representing 50-70% 
of all leukocytes. Over 1011 neutrophils may be produced per day2, and tumors can increase 
this number by even more. Indeed, patients with various cancer types, including but not 
limited to breast, lung and colorectal cancer, often exhibit increased numbers of circulating 
neutrophils3,4. Recent studies have identified key pathways that tumors exploit to disrupt 
normal neutrophil homeostasis and these are discussed below. 
 
Granulopoiesis 
To accommodate for the notably high production and turnover of neutrophils, the bone 
marrow devotes about two-thirds of its space to the formation of neutrophils and monocytes 
Comment [SC1]: I don’t like 
“Homeostasis versus cancer” The 
reader has no idea what we are 
referring to until they read the 
subheading “Granulopoiesis.” What 
about “Neutrophil origins and life 
cycle”? 
 3 
in steady-state conditions5. During granulopoiesis, neutrophils arise from lymphoid/myeloid-
primed progenitors (LMPPs)6, which are derived from hematopoietic stem cells (Figure 1). 
LMPPs further differentiate into granulocyte/monocyte myeloid progenitors (GMPs) and 
many transcription factors required for this process have been identified (reviewed in 5,7,8). 
Neutrophil maturation then begins, as GMPs differentiate through the following sequence: 
myeloblast, promyelocyte, myelocyte, metamyelocyte, banded neutrophil and, finally, a 
segmented neutrophil (reviewed in 5,9-11). The transition from myeloblast to promyelocyte is 
marked by the first appearance of primary granules. Secondary and tertiary granules form 
sequentially during the myelocyte to metamyelocyte and band cell to segmented cell stage, 
respectively5,12. These granules compartmentalize an arsenal of defensive factors and 
enzymes, such as myeloperoxidase, elastase, defensins, cathelicidins and matrix 
metalloproteinases (MMPs), that protect against opportunistic infections and mediate the 
resolution of inflammation (reviewed in 12,13). If large numbers of neutrophils are used up 
during infection or cancer, a process called emergency granulopoiesis overtakes steady 
state granulopoiesis to rapidly increase neutrophil formation11. In tumor-bearing mice and 
humans with pancreatic or colon cancer (and most likely other tumor types), the spleen is an 
alternative source of neutrophil production14. 
 Granulocyte-colony stimulating factor (G-CSF) is the master regulator of neutrophil 
generation and differentiation15-17. G-CSF acts at the level of myeloid progenitors to induce 
their proliferation and differentiation. Its receptor, G-CSFR, is expressed throughout the 
myeloid lineage from early stem and progenitor cells to fully differentiated neutrophils18,19, 
and G-CSFR-STAT3 (signal transducer and activator of transcription 3) signaling governs 
neutrophil formation20. The transcription factor RAR-related orphan receptor γ1 (RORC1) is a 
recently identified regulator of myelopoiesis in tumor-bearing mice and its expression may be 
induced by G-CSF21. However, G-CSF is not absolutely required for granulopoiesis, as other 
molecules – such as granulocyte-macrophage-colony stimulating factor (GM-CSF), 
interleukin 6 (IL-6) and KIT ligand (KITL) – can play a redundant, but lesser role22-24. Tumors 
in many mouse models of cancer upregulate these cytokines, causing overactive 
granulopoiesis and neutrophilia25-31.  
 
Neutrophil retention and release from bone marrow 
One feature of granulocytes that sets them apart from every other immune cell is their 
release from the bone marrow as terminally differentiated, mature cells. Circulating mature 
neutrophils account for only 1-2% of all neutrophils throughout the body under homeostatic 
conditions32. Mature cells are retained in the bone morrow by an interplay between two C-X-
C chemokine receptors, CXCR4 and CXCR2. Constitutive CXCL12 expression by 
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osteoblasts and other bone marrow stromal cells tether CXCR4+ neutrophils in the bone 
marrow, whereas secretion of CXCL1 and CXCL2 by endothelial cells and megakaryocytes 
encourage the release of neutrophils into the circulation via CXCR2 signaling33-38 (Figure 1). 
Several adhesion molecules, such as integrin subunit α4 (ITGA4) and vascular cell adhesion 
molecule 1 (VCAM1), as well as some proteases are also important in neutrophil retention39-
41. In addition to its positive influence on granulopoiesis, G-CSF is a well-known disruptor of 
neutrophil retention42. G-CSF pressures the bone marrow to release neutrophils through 
thrombopoietin (TPO)-induced upregulation of CXCR2 ligands on megakaryocytes38, 
reduction of CXCL12 expression by bone marrow stromal cells43,44 and downregulation of 
CXCR4 on neutrophils themselves45.  
Outside the bone marrow, a cascade of other cell types and cytokines, involving IL-
23-expressing phagocytes and IL-17-producing lymphocytes, tightly regulates the production 
of G-CSF so that neutrophil numbers are maintained in the circulation. In this feedback 
mechanism, macrophages and dendritic cells phagocytose apoptotic neutrophils47-49, curbing 
the secretion of IL-2346 – a cytokine that controls IL-17 expression by αβ T cells, γδ T cells, 
innate lymphoid cells and other lymphocytes50,51. Because IL-17 is upstream of G-CSF52,53, 
lower levels of IL-17 equate to reduced expression of G-CSF and steady-state release of 
neutrophils from the bone marrow46. Commensal bacteria and enterocyte-derived CXCL5 in 
the gut also play a role in neutrophil homeostasis by increasing or inhibiting IL-17 production, 
respectively54,55. IL-1β that is released from dying cells or upregulated in response to 
inflammatory stimuli is another potent inducer of the IL-17-G-CSF axis56,57. 
Many of the molecules that control neutrophil release from the bone marrow are 
frequently upregulated in tumors or systemically as a result of a tumor25-28,58. These factors 
override retention signals in the bone marrow, facilitating neutrophil egress and elevated 
numbers of circulating neutrophils (Figure 2). Cancer cells themselves produce these 
cytokines27,28,58, but stromal and immune cells can also contribute to their elevated 
expression in tumor-bearing mice. For example, tumor-associated macrophages are a well-
known source of IL-1β59. Recently, we showed that neutrophils expand in mammary tumor-
bearing K14-Cre;Cdh1F/F;Trp53F/F mice because of increased macrophage-derived IL-1β 
stimulation of the IL-17-G-CSF axis26. Ectopic overexpression of IL-1β in tumors derived from 
cancer cell lines or a genetically engineered gastric cancer model also increases the number 
of circulating neutrophils60-63. As such, aberrant production of cytokines by tumors or stromal 
cells can offset the balance of neutrophil retention and release from the bone marrow. 
 The pressure on the bone marrow to release neutrophils can often be so intense in 
tumor-bearing hosts that undifferentiated cells are set free prematurely. Nuclear staining of 
circulating neutrophils from mammary and lung tumor models has revealed the existence of 
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ring-like, banded and segmented nuclei26,64-66. We and others recently reported that a 
proportion of these cells express KIT26,31, a marker of lymphoid, myeloid and neutrophil 
progenitor cells25,67, suggesting that these KIT-expressing cells are most likely meta-
myelocytes and/or banded neutrophils67. Circulating neutrophils from breast, lung and 
colorectal cancer patients also show a similar mix of differently shaped nuclei64,68. However, 
the consequence of immature neutrophils in the bloodstream of tumor-bearing hosts is not 
entirely understood. Interestingly, immature neutrophils and neutrophil progenitor cells – 
some of which express KIT – are found in mouse models and patients with inflammation69-73. 
These KIT+ cells differentiate into fully mature neutrophils in situ at sites of Staphylococcus 
aureus infection70,74. Thus, it is tempting to speculate that differentiation at inflammatory sites 
or tumors primes immature neutrophils for functions they would not ordinarily perform.  
The ectopic appearance of immature neutrophils in the circulation may have profound 
consequences on tumor progression. An example of this was shown in mice with chemically 
induced cancer crossed with histamine-deficient mice, where the lack of histamine stalled 
differentiation of immature neutrophils and increased tumor incidence and growth75. These 
data suggest that immature cells have independent functions from mature neutrophils. 
Indeed, the phenotype and behavior of mature, aged neutrophils is not the same as young, 
newly released circulating neutrophils, even in tumor-free mice76. One explanation for the 
difference between immature and mature neutrophil function may be their distinctive 
composition of granules, because granules are synthesized at specific stages of neutrophil 
development12 (Figure 1). Recent studies using density gradient purification methods have 
shown that distinct populations of neutrophils with different ex vivo properties can circulate 
within the same tumor-bearing mouse and individual cancer patients64. Whether these 
populations are truly committed to divergent cell fates or represent cells at assorted stages of 
maturation remains undetermined. 
 
Neutrophil lifespan 
One reason neutrophils have received less attention than other immune cells in the cancer 
arena is the commonly held belief that neutrophil lifespan is too short to influence cancer 
progression. The current paradigm is that circulating neutrophils have a half-life of around 7 
hours in healthy humans2,77 and 8-10 hours in mice78. However, there are an equal number 
of reports challenging these kinetics as too short or too long (reviewed in 79). The 
discrepancy between these studies lies mainly in limits of the methodology and neutrophil 
labeling techniques currently available, and therefore the lifespan of neutrophils in tumor-
bearing hosts is unclear. Animal experiments in calves and mice have shown that a small 
pool of non-circulating neutrophils can survive in tissue for several days80,81. Neutrophils are 
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also retained longer in tumors than in the spleen82, suggesting that the tumor 
microenvironment encourages their survival both locally and systemically. Indeed, pioneering 
work from Mantovani and his colleagues in the 1990s showed that many tumor-associated 
cytokines prolong neutrophil survival in culture83. In line with this, there is evidence that the 
half-life of circulating neutrophils is extended in cancer patients to 17 hours84, which may be 
the result of pro-survival signaling by G-CSF20. A longer life may give neutrophils more time 
to synthesize new molecules and perform additional effector functions during tumor 
progression. 
 
Tumor-induced neutrophil polarization and activation 
One major theme that has emerged from the cancer field is that not all neutrophils are equal. 
Neutrophil polarization leads to divergent phenotypes, depending on specific tumor-derived 
factors. Transforming growth factor β (TGFβ), G-CSF and interferon β (IFNβ) are the most 
well-studied molecules in this process. TGFβ and G-CSF activate a tumor- and metastasis-
promoting program25,27,65,85-88, by regulating the transcription factors inhibitor of DNA 1 (ID1), 
retinoblastoma 1 (RB1) and interferon regulatory factor 8 (IRF8) that control the 
immunosuppressive functions of neutrophils25,87,89,90. IFNβ acts as a negative regulator of the 
pro-tumorigenic phenotype of neutrophils91,92. Cytokine concentration and tumor physiology 
(such as hypoxia) may also be important for neutrophil polarization, because cytotoxic 
neutrophils are shaped into cancer-promoting cells as tumors expand and evolve93. It is 
currently unclear at which differentiation step these molecules instruct phenotypic changes in 
neutrophils. For G-CSF, there is evidence that this cytokine can affect gene expression in 
stem or progenitor cells and fully differentiated cells as G-CSFR is expressed throughout 
neutrophil development18,19. These data suggest that neutrophil polarization is programmed 
early in the developmental process in the bone marrow, but when and where individual 
molecules shape neutrophil polarization needs further attention. Understanding the influence 
of the cytokines discussed here, as well as others, will provide more insights into how 
neutrophil activation goes hand in hand with granulopoiesis. 
Neutrophil polarization states have been divided into ‘N1’ or ‘N2’ categories to mirror 
the Th1/Th2 and M1/M2 nomenclature of T cells and macrophages, respectively65. The study 
introducing the N1/N2 nomenclature noted a difference in neutrophil polarization after 
treating mice bearing subcutaneous mesothelioma tumors with a TGFβ inhibitor. Neutrophils 
in untreated mice supported tumor growth through inhibition of CD8+ T cells, whereas 
neutrophils from TGFβ inhibitor-treated mice opposed tumor growth through their cytotoxic 
ability65. However, knowledge surrounding N1- and N2-polarized neutrophils has not 
progressed much beyond this original study. Their surface markers, cytokine expression 
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patterns, transcription factor regulators and other hallmarks of activation are largely unknown. 
In non-cancerous disease models driven by type 1 or type 2 immunity, the role of neutrophils 
in the disease phenotype is not well understood. It is unclear whether neutrophils respond to 
type 1-associated cytokines (i.e. IFNγ) or type 2-associated cytokines (i.e. IL-4 and IL-13) or 
whether neutrophils produce these cytokines to affect disease phenotype. Although some 
studies addressing these issues are emerging94,95, the lack of concrete evidence in mice or 
humans raises the question of whether the N1/N2 terminology can be applied to cancer-
associated neutrophils. 
The study proposing the N1/N2 terminology characterized N1 neutrophils by a 
hypersegmented nucleus and N2 neutrophils by banded or ring-like nuclei65. Because 
nuclear morphology is a hallmark of neutrophil differentiation10, it is unclear whether the so-
called N2 neutrophils are just immature cells or represent a distinct polarized state, leaving 
the relationship between polarization and maturation unresolved. Nevertheless, the binary 
N1/N2 classification system is most likely an oversimplification of neutrophil polarization for 
the same arguments that have been given against using ‘M1’ and ‘M2’ to describe tumor-
associated macrophages96-98. Similarly to macrophages, neutrophil polarization probably 
exists as a spectrum of activation states, rather than only two extremes. We suggest that 
researchers should follow the recent advances in the macrophage field and apply a 
combinatorial nomenclature that describes neutrophil activation status99. 
A further complication to the picture of neutrophil subtypes is the ongoing debate on 
the kinship of neutrophils and myeloid-derived suppressor cells (MDSCs), and it is currently 
unclear whether these are analogous or separate populations (Box 1). 
 
Neutrophils and tumor initiation 
Over the past two decades, it has become apparent that mutations in normal cells are 
required but not sufficient for tumorigenesis. Inflammation plays an essential role in initiating 
tumorigenesis by damaging specific tissues100, and neutrophils are a critical component of 
this process. Inflammation-induced models of cancer initiated by chemical carcinogens, such 
as the dimethylbenz[a]anthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate (TPA) skin 
cancer model and the azoxymethane (AOM)/dextran sodium sulphate (DSS) colitis-
associated colon cancer model, have established the importance of neutrophils in tumor 
initiation (Figure 3). In these models, neutrophils are attracted to tumor-prone tissues via the 
CXCR2 ligands, CXCL1, CXCL2 and CXCL5101-104. Application of these carcinogens to 
CXCR2-deficient mice, which show impaired neutrophil trafficking, prevents papilloma or 
adenoma formation102,104. Similarly, CXCR2 ligands are increased in several genetically 
engineered mouse models, including the intestinal adenoma ApcMin/+ model, the invasive 
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intestinal adenocarcinoma Ah-CreER;ApcF/+;PtenF/F model and the spontaneous oral 
papilloma K14-CreER;KrasG12D/+ model. In these models, CXCR2 deficiency or inhibition 
retards tumor formation102. However, it should be noted that CXCR2 expression is not 
exclusive to neutrophils. Depletion of the entire neutrophil population using anti-Ly6G 
antibodies phenocopies CXCR2 deficiency and hinders tumorigenesis in both chemically 
induced101,102 and spontaneous tumor models102. In a zebrafish model of HrasG12V-driven 
melanoma, wounding-induced inflammation increases the formation of tumors in a 
neutrophil-dependent manner105. Thus, neutrophils can provide a causal link between 
inflammation and cancer. 
Tumors in various mouse models of KRAS-driven lung cancer – such as Cc10-
Cre;KrasG12D (also known as Ccsp-Cre;KrasG12D), Adeno-Cre;KrasG12D and KrasLA1 models – 
upregulate neutrophil-related chemokines and display expansion of neutrophils90,106-109 
(Figure 2). These phenotypes may be a result of direct upregulation of neutrophil-related 
cytokines like GM-CSF and CXCL8 by KRAS signaling29,30,110. The IL-17-G-CSF axis is 
responsible for expanding neutrophils in at least some of these KRAS models108, but whether 
these cytokines are regulated by KRAS is unknown. As in the chemical-induced colon and 
skin cancer models, depletion of neutrophils or inhibition of CXCR2 signaling reduces the 
number of pulmonary tumors in these KRAS models108,109,111, indicating their dependence on 
neutrophils. The association between KRAS and neutrophils is even stronger in humans and 
mice exposed to cigarette smoke. Cigarette carcinogens cause specific activating mutations 
in KRAS112,113 as well as inflammation and neutrophil accumulation114. These data raise the 
question of whether every KRAS-driven tumor type requires neutrophils for initiation and 
whether KRAS orchestrates their polarization.  
How neutrophils foster tumorigenesis is not completely understood. Neutrophil-
derived elastase and the immunosuppressive ability of neutrophils have both been implicated 
in tumor initiation108,111,115, but the exact mechanisms need further elucidation. Neutrophil 
production of reactive oxygen and reactive nitrogen species (ROS and RNS) and angiogenic 
factors such as MMP9116 may also be important for tumor initiation (Figure 3). In future work, 
genetically engineered mouse tumor models will be extremely valuable in this area of cancer-
related neutrophil biology, as they allow neutrophils and neutrophil-derived factors to be 
manipulated as tumors arise de novo. 
 
Neutrophils and tumor growth 
Early studies on neutrophil function during tumor growth set the stage for the ongoing 
discussion over when and how neutrophils can be anti-tumorigenic or pro-tumorigenic. More 
than two decades ago, it was shown that neutrophils can mediate tumor rejection of 
transplanted G-CSF-producing colon cancer cells into mice117. A few years later, an opposing 
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tumor-promoting role was uncovered when mice bearing transplantable tumors that were 
depleted of neutrophils via anti-Gr1 antibody showed reduced tumor growth118,119. 
Since then, the literature showing a tumor growth-promoting role for neutrophils in 
vivo has largely outweighed the studies showing an opposite effect. One mechanism 
neutrophils employ to promote tumor growth is the induction of angiogenesis (Figure 3), and 
neutrophil depletion decreased tumor growth and microvessel density in both transplantable 
and spontaneous tumor models65,85,91,120-123. Blocking CXCR2 signaling or transplanting 
cancer cell lines into CXCR2-deficient mice recapitulated these effects58,124,125. In other 
studies, co-injection of cancer cell lines with neutrophils isolated from tumor-bearing mice 
increased tumor growth and angiogenesis126, underscoring their ability to perpetuate 
proliferation. Several mitogenic and pro-angiogenic molecules have been implicated in 
neutrophil-driven tumor growth including elastase, prokineticin 2 (PROK2, also known as 
BV8) and MMP9115,120,126-129. Immunosuppression – through amino acid depletion or specific 
cytokine release – is another predominant mechanism neutrophils use to facilitate tumor 
progression130. Data from other disease models indicate that neutrophils are important 
players in directing adaptive immune responses (reviewed in 131), but apart from their effects 
on cytotoxic T lymphocytes, many of the underlying mechanisms by which this is achieved 
are unknown in cancer. More recently, a new pro-tumorigenic function of neutrophils 
emerged showing that these cells counteract senescence via IL-1RA to promote prostate 
cancer progression in a PTEN-deficient autochthonous model132.  
 Even though the literature on anti-tumorigenic neutrophils is less abundant, there 
have been some intriguing new data in this area. For example, neutrophils in mice with 
transplanted MMTV-PyMT;MMTV-cMyc mammary tumors hindered tumor growth133, 
presumably through their cytotoxic effects mediated by H2O2. Neutrophil specific-deletion of 
MET, the hepatocyte growth factor (HGF) receptor, impaired recruitment of neutrophils to 
tumors and led to enhanced tumor growth of various transplantable cell lines and in a 
spontaneous liver cancer model134. Expression of MET in neutrophils was upregulated by 
endothelial cell- and cancer cell-derived tumour necrosis factor (TNF) in this study134; 
whereas others have shown that TNF signaling in CD4+ T cells led to increased IL-17 levels 
and neutrophil accumulation in ovarian tumor-associated ascites121. These data suggest that 
the control of neutrophil behavior by TNF is context dependent. Notably, there are 
contradictory results regarding neutrophil function using the same transplantable cell lines. 
Some studies reported a pro-tumorigenic role of neutrophils, whereas other studies reported 
no effects in the 4T1 mammary85,133 and the Lewis lung cancer (LLC)134,135 models. The 
timing of neutrophil depletion experiments may be critical for the interpretation of these data, 
as neutrophil function evolves from anti-tumoral to pro-tumoral in mice bearing transplantable 
cancer cell lines93. Antibody-dependent cellular cytotoxicity (ADCC) is another mechanism 
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neutrophils can use to kill cancer cells after antibody therapy (reviewed in 136). It remains to 
be seen whether ADCC occurs in vivo without exogenous antibodies, as cancer-induced 
endogenous antibodies are known to activate pro-tumoral programs in myeloid cells via Fc 
receptors137,138. Taken together, more research emphasis should be put on determining the 
context in which neutrophil behavior is modulated.  
 Several studies demonstrated the importance of neutrophils in tumor progression by 
blocking neutrophil recruitment to tumors, usually via CXCR2 inhibition. For instance, 
prostate cancer cells in Probasin-Cre4;PtenF/F;Smad4F/F mice upregulated CXCL5 via the 
Hippo-YAP1 pathway and blocking YAP1 or CXCR2 decreased immunosuppressive 
neutrophil recruitment to tumors and blunted tumor proliferation139. Less attention has been 
directed at understanding whether these recruitment factors are also important for neutrophil 
effector functions. In a de novo model of endometrial adenocarcinoma, progesterone 
receptor (Pgr)-Cre;PtenF/F mice, blockade of neutrophil recruitment by genetic deletion of G-
CSFR or CXCR2 increased uterine tumor burden140. Hypoxia-induced CXCL1, -2 and -5 
recruited neutrophils, and these cells impeded tumor growth by promoting cancer cell 
detachment from the basement membrane via modulation of integrins. Interestingly, 
neutrophils deficient in MyD88 signaling maintained their trafficking ability, but lost their anti-
tumorigenic functions140. These data suggest that CXCR2 ligands regulate neutrophil 
recruitment, not function. Future work should focus on whether the same is true for every 
tumor type and whether neutrophil-recruiting molecules can be uncoupled from neutrophil-
activating molecules. 
 
Tumor metastasis 
Most neutrophil-centered studies published in the cancer field over recent years pertain 
specifically to metastasis. Neutrophils actively participate in different steps of the metastatic 
cascade: cancer cell escape from the primary tumor, intravasation into the blood and/or the 
lymphatic vascular system, survival in circulation, extravasation into distant organs and 
outgrowth of metastases (Figure 4). As early as the late 1980s – before the importance of 
neutrophils in primary tumor growth was established117-119 – co-injection of cancer cells and 
neutrophils from tumor-bearing rodents intravenously was shown to increase experimental 
lung metastases141,142. Although these studies substantiated the pro-metastatic ability of 
neutrophils, this research area is surrounded by controversy, as opposing roles for 
neutrophils exist in the literature and often within the same model system.  
 
The pro-metastatic role of neutrophils 
A large body of literature indicates that neutrophils are most important during the early steps 
of the metastatic cascade. Enhanced retention of human melanoma cells in lungs can be 
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seen as early as 24 hours after co-injection with neutrophils into nude mice143. In 
experimental lung or liver metastasis models where cancer cell lines are injected into the 
circulation or spleen, respectively, systemic depletion of neutrophils (via anti-Gr1 antibodies) 
reduces the formation of metastases144,145. Intravital imaging has shown that cancer cells co-
localize with endothelial cell-associated neutrophils in a CD11b-dependent manner144, 
suggesting that neutrophils guide cancer cells into tissues and/or retain them there rather 
than supporting the outgrowth of secondary tumors. Neutrophils use neutrophil extracellular 
traps (NETs) for this purpose to sequester circulating cancer cells in a mesh of nucleic acids, 
antimicrobial factors and enzymes, and to promote adhesion at distant organ sites146. In vitro, 
NETs also stimulate cancer cell migration and invasion146. 
Experimental metastasis models bypass several initial steps of the metastatic 
cascade, including exit from the primary tumor, intravasation and priming of the pre-
metastatic niche. Spontaneous models of metastasis indicate that neutrophils are important 
for intravasation and formation of the pre-metastatic niche. As mentioned above, neutrophils 
are potent effectors of angiogenesis147, providing cancer cells with more routes of escape. 
Neutrophils can also direct cancer cells towards endothelial cells to promote intravasation 
into the circulation. For example, melanomas in Hgf-Cdk4R24C mice exposed to ultraviolet 
(UV) light showed cancer cell clustering around blood vessels and increased lung metastasis 
but no effects on primary tumor growth148. In this setting, UV-induced damage to 
keratinocytes increased the levels of high mobility group box 1 (HMGB1), which recruits 
TLR4+ neutrophils to primary tumors. These neutrophils then facilitate cancer cell 
angiotropism and metastasis. In vitro, neutrophil-derived TNF stimulates the migration of 
melanoma cells, suggesting that TNF is at least one factor that neutrophils produce in vivo to 
initiate metastasis148. The same study found that ulcerated melanomas and the 
accompanying neutrophilic influx in patients are associated with greater melanoma-
endothelial cell interactions and higher metastatic incidence. These data are supported by 
another study showing a strong correlation between neutrophil infiltration and the extent of 
ulceration105. Taken together, these studies indicate that neutrophils initiate interactions 
between cancer cells and endothelial cells in the vicinity of the primary tumor 
microenvironment to expedite metastasis. 
An interesting consequence of tumor expansion at the primary site is the 
accumulation of neutrophils in visceral organs before the arrival of disseminated cancer 
cells25,26,28,133,149-152, in what has been termed the pre-metastatic niche153. This accumulation 
of neutrophils in distant organs is highly reminiscent of the swarming behavior of neutrophils 
that occurs after injury, which is stimulated by neutrophil-derived leukotriene B4 (LTB4), a 
lipid by-product of the arachidonate 5-lipoxygenase (ALOX5) enzyme154. Recent data 
showed that LTB4 production by neutrophils in the pre-metastatic niche supports LTB4 
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receptor+ metastasis-initiating cells in the MMTV-PyMT mouse model, and that inhibition of 
ALOX5 reduces pulmonary metastasis without affecting primary tumor growth152. But why do 
these neutrophils accumulate in pre-metastatic organs? In tumor-bearing mice, primary 
tumors release factors that systemically condition distant sites for future metastases. 
Neutrophil accumulation at distant sites is G-CSF-dependent in some tumor models25,26,28,152; 
however, the original studies characterizing CD11b+ myeloid cell recruitment to the pre-
metastatic niche implicated vascular endothelial growth factor A (VEGFA), TNF and 
TGFβ153,155.  
Some or all of these tumor-derived factors may also dictate whether neutrophils 
promote metastasis at distant locations. Indeed, the genetic loss of TGFβR2 or TGFβ 
signaling blockade in neutrophils decreased lung metastasis in the 4T1 mammary tumor 
model86,88. Interestingly, the TGFβ-induced immunosuppressive function of neutrophils 
occurs through an autocrine loop that is activated by regulatory B cells (Breg cells)
88. G-CSF 
is another factor that drives a pro-metastatic phenotype in neutrophils, and G-CSF 
presumably stems directly from cancer cells in the 4T1 model27,28. G-CSF induces 
PROK2/BV8 expression in neutrophils26,156, which may induce cancer cell migration or 
vascular leakiness to support metastasis28,128,129. We recently identified another mechanism 
whereby G-CSF modulates neutrophil phenotypes and pro-metastatic functions26. In this 
mechanism, a systemic inflammatory cascade involving the secretion of IL-1β by mammary 
tumor-associated macrophages leads to IL-17 expression by γδ T cells and subsequently 
raises systemic G-CSF levels. G-CSF then stimulates neutrophil expansion and converts 
neutrophils into immunosuppressive cells that block the anti-tumor functions of CD8+ T cells, 
allowing disseminated cancer cells to evade immune detection26. Thus, both cancer cells and 
immune cells can educate the pro-metastatic abilities of neutrophils. 
Neutrophil precursors are found ectopically in organs where metastases commonly 
occur. In the K14-Cre;Cdh1F/F;Trp53F/F mouse breast cancer model, we noted that a 
proportion of neutrophils in various tissues express KIT and display a mixed nuclear 
morphology26. Others have identified KIT-expressing cells in the pre-metastatic niche28,153,157. 
Antagonizing KIT signaling or inhibition of KIT ligand (KITL) expression by cancer cells 
prevents pulmonary metastasis formation in the 4T1 model31, suggesting a pro-metastatic 
role for KIT+ neutrophils. In addition, C-C chemokine ligand 9 (CCL9)-CCR1 signaling 
mediates colon cancer metastasis through recruitment of immature myeloid cells and mature 
neutrophils158,159. These data indicate that the release of neutrophil precursors from the bone 
marrow supports metastatic progression. 
 
The anti-metastatic role of neutrophils 
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In stark contrast to the studies above that described a metastasis-promoting role for 
neutrophils, others have shown that depletion of neutrophils increases metastasis133,160. The 
H2O2-mediated cytotoxic behavior of these anti-metastatic neutrophils is controlled by 
CCL2133. However, G-CSF still controls the transcriptional activity and expansion of 
neutrophils26-28. Controversially, these studies used the 4T1 mammary tumor cell line to show 
an anti-metastatic role133, whereas other laboratories have used the same cell line to 
demonstrate a pro-metastatic role of neutrophils28,88,150. So, how can different studies of 
neutrophils produce contradictory results using the same cell line? The timing of neutrophil 
depletion experiments may be critical, as neutrophils isolated from early-stage tumors exhibit 
different behavior than neutrophils from late-stage tumors93,161. Another possibility may be 
that the cell lines used by independent labs are not actually the same at all. It is well known 
that in vitro culture places a selection bias on cancer cells, making them more prone to 
genetic drift162. As a result, the ‘same’ cell lines may diverge in the cytokines they produce. 
Likewise, the introduction of ectopic transgenes, such as luciferase or green fluorescent 
protein (GFP), may skew the secretome, immunogenicity or behavior of these cells. 
Microbiome differences between experimental animal cohorts may also influence neutrophil 
behavior in conflicting ways. Indeed, neutrophil ageing is controlled by the microbiota in 
tumor-free mice76. 
In addition to their production of H2O2
133,160, neutrophils can also limit the formation of 
metastases through their expression of thrombospondin 1 (TSP1)163 and MET134 in 
experimental metastasis models. However, pro-metastatic neutrophils deactivate TSP1 by 
elastase- and cathepsin G-mediated degradation after degranulation in lung tissue, and 
inactivation of TSP1 contributes to metastasis formation164. Interestingly, TSP1 can be 
induced in neutrophils by a peptide derived from prosaposin, a precursor of sphingolipid 
activator proteins, and treatment of MDA-231-LM2 mammary tumor-bearing mice with this 
peptide reduced spontaneous formation of pulmonary metastases without affecting primary 
tumor growth163. These data provide proof of principle that the pro-metastatic behavior of 
neutrophils can be switched in vivo, and could open up possible avenues of therapeutic 
intervention. 
 
Clinical implications 
Neutrophils as biomarkers in cancer patients 
Although experimental studies have highlighted multifaceted and sometimes opposing roles 
of neutrophils in cancer, the bulk of clinical evidence assessing neutrophil to lymphocyte 
ratios (NLRs) mostly supports the notion that neutrophils promote, rather than inhibit, cancer 
progression3. The NLR has thus been proposed to be an attractive biomarker for risk 
stratification of patients with cancer and to guide treatment decisions. NLRs can easily and 
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cost effectively be determined using standard blood analyses. That said, at the level of 
individual patients, it might be challenging to translate a given NLR into a personalized 
prognosis or treatment plan due to the large variability in neutrophil levels between healthy 
individuals165. In addition, the variation in the reported NLR cutoff points used to allocate 
patients to high or low risk cohorts complicates the use of a single NLR determination for 
patient diagnostics and treatment.  
To maximize the clinical utility of systemic neutrophil scores, it may be more 
informative to perform longitudinal measurements of NLR in individual patients. A rise in 
neutrophil counts and/or NLR over time may indicate disease recurrence or progression, and 
a drop in these values after initiation of therapy may indicate a good response. Thus far, a 
limited number of studies have attempted this approach. For example, in colorectal cancer 
patients, surgical removal of the primary tumor reduces the NLR in a proportion of patients, 
and a post-surgical low NLR is associated with improved survival166. Patients who have 
metastatic renal cell carcinoma with a low pre-treatment NLR that is maintained during 
treatment with tyrosine kinase or mTOR inhibitors experience a more favorable outcome167. It 
will be interesting to assess whether parallel scoring of patient serum levels of neutrophil-
activating and polarizing soluble mediators, including IL-1β, IL-17, G-CSF, GM-CSF and/or 
TGFβ, increases the prognostic or predictive power of NLR measures. 
In comparison to NLR, the prognostic and predictive power of intratumoral neutrophils 
is murkier and more variable, and positive (gastric168), negative (renal169, melanoma170) or no 
(lung171) correlation with patient outcome has been observed in different studies. Colorectal 
cancer is one example where controversy surrounds the potential role of intratumoral 
neutrophils172,173. The markers used to identify tumor-associated neutrophils (such as CD66b, 
myeloperoxidase and cell morphology by haematoxylin and eosin staining) may explain 
these discrepancies, as expression of these markers in neutrophils may vary in different 
tumor microenvironments. NLR is more reliable in this way because blood neutrophils are 
easily separated from other immune cells by flow cytometry. Employing combinatorial 
markers in tumor sections based on neutrophil polarization may provide some clarity. In fact, 
combinatorial approaches involving assessment of the expression of multiple neutrophil-
related genes have been recently applied to data sets from thousands of patients with cancer. 
Two independent studies found that the enrichment of neutrophil-associated genes 
correlates with poor prognosis when encompassing all solid tumor types4,140. Thus, moving 
beyond single markers may be necessary to accurately determine whether the numbers of 
intratumoral neutrophils has prognostic or predictive power.  
 
Neutrophils as therapeutic targets in cancer patients 
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Neutrophils and their associated soluble mediators not only serve as prognostic and/or 
predictive biomarkers in cancer patients, but the versatile functions of neutrophils in cancer 
biology may also represent therapeutic targets. A relatively straightforward approach to 
target neutrophils in cancer types in which they are detrimental is via inhibition of their 
trafficking or activation. Importantly, the cancer field can take advantage of neutrophil-
targeting agents that are being developed for the treatment of inflammatory and autoimmune 
diseases. For example, ongoing clinical trials with a CXCR2 antagonist in patients with 
chronic obstructive pulmonary disease have shown that treatment results in decreased 
absolute neutrophil counts, reduced inflammatory biomarkers and reduced disease 
symptoms174. The first clinical trials with reparixin, a CXCR1 and 2 inhibitor175, are ongoing in 
cancer patients176,177. Importantly, characterization of neutrophil polarization in different tumor 
types as well as at early and late stages is urgently needed in order to maximize the utility of 
therapeutic modalities. In tumors in which neutrophils are beneficial, such as early stage lung 
cancer161, strategies to magnify their anti-tumor abilities should be explored. 
Another neutrophil-associated pathway under intense investigation is the IL-23-IL-17 
axis (reviewed in 51). The US Food and Drug Administration (FDA) approved antagonists 
targeting IL-12p40 (a subunit of IL-23) in 2009 and IL-17 in 2015 for the treatment of 
psoriasis, and these agents substantially improve quality of life in people with this disease. It 
would be interesting to investigate whether these already existing drugs are efficacious in 
cancer patients because pre-clinical models and clinical samples indicate that this pathway is 
important for cancer progression26,68. Therapeutic strategies aimed at re-polarizing tumor-
induced neutrophils or interfering with their downstream pro-tumorigenic effects could offer 
additional opportunities for intervention65,152. 
 
Combining neutrophil targeting with other anti-cancer therapies 
Successful implementation of neutrophil-targeting approaches in the clinic will require a 
critical assessment of the most optimal combination therapy strategies. In this regard, we can 
learn from the growing number of mechanistic studies performed in clinically relevant mouse 
tumor models that have addressed the impact of neutrophils on the efficacy of anti-cancer 
therapies. As mentioned above, neutrophils are important mediators of angiogenesis, so 
perhaps it is no surprise that neutrophils induce refractoriness of experimental tumors to anti- 
VEGFA therapy in an IL-17- and G-CSF-dependent fashion178-180. These data suggest that 
simultaneous inhibition of neutrophils and anti-angiogenic therapy might be an effective anti-
cancer strategy. Indeed, therapeutic synergy is observed when anti-VEGFA therapy is 
combined with depletion of neutrophils via anti-Gr1 or anti-G-CSF antibodies179,181. 
Chemotherapy is another combination partner for neutrophil-targeting therapeutics; 
however, many types of chemotherapy negatively affect neutrophil production themselves. 
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Interestingly, chemotherapy-induced neutropenia is associated with improved survival in 
patients with non-small cell lung, breast, gastric or colorectal cancer182-185. This beneficial 
association may be explained by two reasons, one of which is neutrophil-independent and 
the other neutrophil-dependent. Because neutropenia is a surrogate marker of chemotherapy 
efficacy, lack of neutropenia in patients may indicate insufficient dosing and inadequate 
tumor killing. Alternatively, the patient survival benefit of chemotherapy-induced neutropenia 
may arise from reducing the neutrophils that counteract the efficacy of chemotherapy. A 
growing number of experimental studies have attempted to design strategic combination 
therapies, and some studies reported a beneficial role for neutrophils in chemotherapy 
responses, whereas others indicated that neutrophils counteract the anti-cancer efficacy of 
chemotherapy (recently reviewed in 186). For example, depletion of Gr1+ myeloid cells or 
Ly6G+ neutrophils reduced the anti-cancer efficacy of cyclophosphamide and doxorubicin in 
tumor inoculation models187,188. These data contrast to the improved tumor inhibition 
achieved by combining CXCR2 blockade with doxorubicin, cyclophosphamide or docetaxel in 
xenograft and de novo tumorigenesis mouse models58,132. Moreover, some 
chemotherapeutics, such as gemcitabine and 5-fluorouracil, directly reduce the viability 
and/or change the functionality of myeloid cells, which then influences the anti-cancer 
efficacy of these drugs. These drugs trigger IL-1β secretion from immunosuppressive 
monocytes and neutrophils, setting off a chain of inflammatory events that resulted in a 
reduced efficacy of chemotherapy on subcutaneous EL4 thymomas in mice189. 
Another unresolved issue is the clinical benefits and risks of using recombinant G-
CSF and GM-CSF to counteract chemotherapy-induced neutropenia. Neutropenia 
predisposes patients to life-threatening infections, therefore recombinant G-CSF or GM-CSF 
is commonly prescribed to counteract reduced neutrophil numbers brought on by 
chemotherapy and to lessen therapy-induced mortality190,191. However, experimental studies 
indicate that G-CSF polarizes neutrophils towards a pro-tumorigenic phenotype and 
promotes metastasis formation25-28,87. Two experimental studies examining tumor growth 
after combining chemotherapy with G-CSF neutralization reported contradictory results28,192, 
leaving the debate open. Therefore, it is critical to carefully assess whether the beneficial 
effect of G-CSF in reducing susceptibility to infections outweighs its potential risk of 
accelerating disease progression in cancer patients. 
Contrasting data also exist about the function of neutrophils in radiotherapy 
responses. Whereas anti-Ly6G antibody-mediated neutrophil depletion improves the efficacy 
of radiotherapy in a subcutaneous colon cancer model193, antibody-mediated depletion of 
Gr1+ cells does not alter radiotherapy responses of xenografted prostate cancer cells194. 
Taken together, the diverse and sometimes contradictory roles of neutrophils in anti-cancer 
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therapy responses may reflect differences in tumor type, tumor model, immune status of the 
host and mechanism of tumor killing by a particular anti-cancer therapy. 
A promising therapeutic avenue is the combination of T cell checkpoint inhibitor 
immunotherapy with neutrophil manipulation195. Despite the success of immune checkpoint 
blockade, disease progression remains unabated in a significant proportion of treated 
patients196. Relieving neutrophil-induced immunosuppression may be one way to improve 
immunotherapy. Indeed, experimental studies have shown that anti-programmed cell death 
protein 1 (PD1) or anti-PD1 and anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA4) 
synergizes with anti-CXCR2 or anti-Ly6G, respectively, to delay tumor growth197,198. These 
studies support the concept that combining cancer immunotherapies with neutrophil 
suppression may increase therapeutic benefit. 
In addition to T cell-based immunotherapies, macrophage inhibitors such as anti-
colony stimulating factor 1 receptor (CSF1R) are also gaining traction in the clinic199. Data 
from a genetically engineered skin cancer model and transplantable mammary tumor models 
indicate that neutrophil infiltration into tumors and their systemic expansion is increased 
following macrophage blockade via CSF1R or CCR2 signaling200,201. Given the tight interplay 
between neutrophils and macrophages131, neutrophils may be expected to promote 
resistance to macrophage-targeting therapies. In fact, neutrophils have been shown to 
mediate resistance to the anti-angiogenic drug sorafenib after macrophages are blocked in 
the RIP1-Tag2 pancreatic and MMTV-PyMT mammary tumor mouse models202. Thus, 
targeting one myeloid cell population may require additional targeting of another myeloid cell 
population to counteract therapeutic resistance. 
 
Conclusion and perspectives 
The influential role of neutrophils on cancer biology and their potential as therapeutic targets 
are now widely recognized. Recent data have shed light on this underappreciated cell type, 
while at the same time, dispelling the myth of neutrophil neutrality. Currently, the complex 
roles of neutrophils in cancer not only include their ability to promote or prevent tumor 
progression, but also encompass various polarization states. Each of these realizations 
opens up new opportunities for therapeutic intervention. A recurring theme from recent 
literature that may help in the design of novel neutrophil-targeting, anti-cancer therapies is 
the crosstalk between neutrophils and other immune cell populations (Table 1). Interestingly, 
several of these communication networks mirror the same pathways in other disease 
models94,203, suggesting that neutrophil-related inhibitors designed for specific inflammatory 
conditions may also be useful in cancer patients.  
To gain a better understanding of these pathways and to discover new ones, 
sophisticated animal models that allow selective neutrophil manipulation are desperately 
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needed. Neutrophils die quickly during ex vivo culture limiting the utility of this technique; 
therefore, neutrophil biology is best studied in vivo. Researchers commonly use two 
antibodies to deplete neutrophils, anti-Gr1 and anti-Ly6G, but these invaluable tools are far 
from foolproof. Anti-Gr1 also affects inflammatory monocytes and other Ly6C-expressing 
cells204, and neutrophils quickly reappear after antibody depletion in tumor-bearing mice205. 
Recently, a mouse model based on Ly6g-driven Cre recombinase was developed, the 
Catchup mouse, which includes a fluorescent reporter allowing the function of mature 
neutrophils to be monitored via in vivo imaging206. One value of this model stems from its 
ability to specifically delete neutrophil-derived molecules at later stages of these cells’ 
differentiation. We predict that this model and others like it will provide valuable information 
about the involvement of neutrophils and their molecular products in tumor initiation, growth 
and metastasis. These models may also generate novel findings in other less-studied areas 
of neutrophil biology, including the metabolic processes that occur during their tumor-related 
functions. For the unresolved issues – such as the relationship between neutrophil 
polarization and maturation, as well as neutrophils versus granulocytic or polymorphonuclear 
(G/PMN)-MDSCs  – single cell sequencing or single cell fate-mapping reporter tools should 
be coupled with identification of nuclear morphology and surface marker expression to better 
define the differences between activated neutrophils and immature cells. Together, these 
new methodologies are destined to provide novel insights into the not-so-neutral behavior of 
neutrophils in cancer and other diseases. 
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Box 1: Neutrophils and MDSCs 
Myeloid-derived suppressor cells (MDSCs) is a name assigned to a group of myeloid cells 
that suppress immune responses and express CD11b and Gr1 (reviewed in 130,207). The 
appearance of MDSCs is a consequence of a pathological condition, such as cancer, 
infection and inflammation, driven by the aberrant expression of cytokines. These cells are 
rarely, if ever, found in homeostatic conditions. MDSCs encompass many immune cells at 
various stages of differentiation because of the non-specific nature of the Gr1 antibody used 
to identify them (clone RB6-8C5). Gr1 binds two antigens, Ly6C and Ly6G, which identify two 
major cellular subsets in tumor-bearing mice: CD11b+Gr1high cells referred to as granulocytic 
or polymorphonuclear (G/PMN)-MDSCs and CD11b+Gr1low monocytic (M)-MDSCs. These 
two populations are more accurately recognized by the use of specific Ly6G (clone 1A8) and 
Ly6C antibodies: CD11b+Ly6G+Ly6Clow neutrophils and CD11b+Ly6G—Ly6C+ monocytes. 
Because G/PMN-MDSCs and neutrophils share a common set of markers and are 
morphologically identical, there is a great deal of controversy and confusion surrounding the 
relationship between these cells. There is currently no way to uniquely identify one cell type 
from the other, so the question of whether neutrophils and G/PMN-MDSCs are distinct 
populations remains unanswered. Immaturity is often attributed to G/PMN-MDSCs as a 
feature that distinguishes them from fully differentiated neutrophils130,207. However, Gr1 and 
Ly6G recognize both mature and immature cells, so it is not technically possible to separate 
neutrophils from their precursors based on these markers. The assumption that all 
CD11b+Gr1+ cells in tumor-bearing mice are MDSCs should be avoided because not all 
CD11b+Gr1+ cells are immunosuppressive in tumor-bearing mice138,208. Thus, data in the 
literature need to be interpreted with caution. 
In our view, the MDSC nomenclature is self-limiting. Assigning a name to a cell or 
group of cells based on one function such as immunosuppression implies that G/PMN-
MDSCs predominately exist for one purpose or are incapable of performing any other activity. 
Myeloid cells are extremely dynamic and adaptable cells that carry out many different 
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functions simultaneously. In fact, neutrophils can be both pro-angiogenic and 
immunosuppressive178. This reality is often overlooked, because individual studies often 
focus on one particular functional aspect of a cell population while other functions remain 
untested. Therefore, we suggest that the use of the restrictive term MDSCs be reevaluated, 
and until convincing evidence is generated that distinguishes neutrophils from G/PMN-
MDSCs, we consider G/PMN-MDSCs as neutrophils with immune suppressive capabilities. 
 
 
Figure legends 
Figure 1: Granulopoiesis during homeostasis. Neutrophil development in the bone 
marrow starts in the stem cell niche. A self-renewing long-term hematopoietic stem cell (LT-
HSC) differentiates into a short-term hematopoietic stem cell (ST-HSC) and subsequently a 
multipotent progenitor (MPP) that has lost its self-renewing capacity. MPPs give rise to 
lymphoid/myeloid-primed progenitors (LMPPs). LMPPs differentiate into 
granulocyte/monocyte progenitors (GMPs), which in turn give rise to granulocytes5,6,19. When 
GMPs commit to neutrophil generation under the direction of granulocyte-colony stimulating 
factor (G-CSF) or granulocyte-macrophage-colony stimulating factor (GM-CSF), myeloblasts 
differentiate from a promyelocyte, a myelocyte and a metamyelocyte into a band cell, and 
finally, into a mature, hypersegmented neutrophil10. During its differentiation, the developing 
neutrophil changes its nuclear morphology from a round shape to a banded morphology into 
a segmented shape. Developing neutrophils express G-CSFR throughout the myeloid 
lineage18. As neutrophils mature, they downregulate expression of various receptors, 
including KIT, VLA4 (also known as integrin β1) and C-X-C chemokine receptor 4 (CXCR4), 
while upregulating CXCR2 and Toll-like receptor 4 (TLR4). Under steady state conditions, 
ligands for KIT, VLA4 and CXCR4 (such as KITL, vascular cell adhesion molecule 1 
(VCAM1) and CXCL12, respectively) are produced by the bone marrow stroma to retain the 
progenitor cells. Ligands for CXCR2, including CXCL1, -2, -5, and -8 (in humans only) are 
expressed outside the bone marrow when neutrophils need to be mobilized34,37,41. 
Neutrophils have three types of granules and other secretory vesicles that contain specific 
effector proteins – of which a selection is shown here – and these emerge during distinct 
developmental stages. Primary (azurophil) granules appear during the myeloblast to 
promyelocyte stage, secondary (specific) granules appear during the myelocyte to 
metamyelocyte stage, tertiary (gelatinase) granules appear during the band cell to 
segmented cell stage of development, and secretory vesicles appear only in mature 
neutrophils. A variety of transcription factors regulate commitment to the neutrophil lineage 
and subsequent developmental stages5,7,8. A selected list of these transcription factors and 
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their expression levels during maturation are shown at the bottom of the figure. Under 
homeostatic conditions, only fully differentiated neutrophils exit the bone marrow into the 
circulation. CR1, complement receptor type 1; IRF8; interferon regulatory factor 8; MMP9, 
matrix metalloproteinase 9; MPO, myeloperoxidase; NE, neutrophil elastase; STAT3, signal 
transducer and activator of transcription 3.  
 
Figure 2: Tumor-induced emergency granulopoiesis. Tumors affect both the 
development and the release of bone marrow neutrophils. Tumor-induced increases in the 
levels of granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage-colony 
stimulating factor (GM-CSF) skew hematopoiesis towards a myeloid cell production, greatly 
increasing the generation of granulocyte/monocyte progenitors (GMPs) and neutrophil 
progenitors25-29,58. In addition, tumors interfere with neutrophil retention in the bone marrow 
by upregulating various cytokines and chemokines. The composition of these mediators 
depends on the tumor type, mutations and oxygen levels in the tumor. The expression of KIT 
ligand (KITL) and the C-X-C chemokine receptor 2 (CXCR2) ligands CXCL1, 2 and 5 by 
cancer cells increases in response to hypoxia31,140. KRAS signaling, as well as loss of PTEN 
or SMAD4, in cancer cells increases expression of GM-CSF and several ligands of CXCR2, 
including CXCL1, 2, 5 and 830,106,109,110,139. In addition, cancer cells either directly or indirectly 
– through interleukin (IL)-1² -producing macrophages and IL-17-producing ³ ´  T cells – 
produce G-CSF25,26. Neutrophil-derived BV8 also induces neutrophil expansion128,129. This 
pressure on the bone marrow emanating from the tumor causes increased generation and 
release of immature (from GMP to banded cells) and mature neutrophils into the 
circulation26,64-66. ECM, extracellular matrix; LMPP, lymphoid/myeloid-primed progenitor; LT-
HSC, long-term haematopoietic stem cell; MPP, multipotent progenitor; ST-HSC, short-term 
haematopoietic stem cell. 
 
Figure 3: Neutrophil function in tumor initiation and growth. There are several 
mechanisms by which neutrophils either promote or limit tumorigenesis. Transformation of an 
epithelial cell to a cancer cell can be supported by the production of reactive oxygen species 
(ROS) or reactive nitrogen species (RNS) and proteases by neutrophils. These molecules 
induce epithelial damage and subsequent tumor-promoting inflammation. Epithelial damage 
by wounding also recruits neutrophils by prostaglandin E2 (PGE2) to promote tumor 
initiation105. Promotion of tumor growth can also be mediated by crosstalk between 
neutrophils that are activated by tumour necrosis factor (TNF)-induced interleukin (IL)-17-
producing CD4+ T cells121. In addition to tumor initiation, neutrophils promote progression of 
tumor growth by converting senescent cancer cells into proliferating cancer cells via IL-1 
receptor antagonist (IL-1RA)132. Proliferation is directly stimulated by transfer of neutrophil 
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elastase (NE) to cancer cells, which causes the degradation of insulin receptor substrate 1 
(IRS1) and activates PI3K signaling115. Neutrophils express inducible nitric oxide synthase 
(iNOS) or arginase 1 (ARG1) to suppress CD8+ T cell-mediated anti-tumor immune 
responses and promote tumor progression. Immunosuppression can also be accomplished 
by transforming growth factor β (TGF² ) signaling in neutrophils65,88. In some contexts 
neutrophils can also limit tumor growth. Hypoxia in the tumor induces expression of C-X-C 
ligands (CXCL)1, -2 and -5 to recruit anti-tumor neutrophils140. Upregulation of MET on 
neutrophils by endothelial-derived TNF causes these cells to produce iNOS, which has 
cytotoxic effects on cancer cells134. Lastly, neutrophils participate in remodeling of the 
extracellular matrix (ECM) and induce angiogenesis by BV8 production and activation of 
vascular endothelial growth factor A (VEGFA) by matrix metalloproteinase 9 (MMP9)116,120,126-
129.  
 
Figure 4: Impact of neutrophils on the metastatic cascade. Neutrophils influence several 
steps of metastasis. In melanoma, ultraviolet (UV) radiation causes release of high mobility 
group box 1 (HMGB1) from keratinocytes, which recruits neutrophils through Toll-like 
receptor 4 (TLR4) signaling. These neutrophils induce migration of cancer cells towards 
endothelial cells by tumour necrosis factor (TNF), leading to enhanced metastasis148. In 
mammary tumors, interleukin (IL)-1β-expressing macrophages instigate IL-17-producing ³ ´  T 
cells, resulting in a granulocyte-colony stimulating factor (G-CSF)-dependent systemic 
expansion of neutrophils. At the metastatic site, these neutrophils limit anti-tumor CD8+ T cell 
responses by producing inducible nitric oxide synthase (iNOS)26. In addition, regulatory B 
(Breg) cells instruct neutrophils to limit T and NK cell responses to the metastatic lesion
88. 
Neutrophils can support leukotriene B4 (LTB4) receptor-positive metastasis-initiating cancer 
cells by producing LTB4 at the metastatic site152. Neutrophils also capture circulating cancer 
cells by direct interactions using the cell surface molecule CD11b or by releasing neutrophil 
extracellular traps (NETs), which are associated with increased formation of metastases144,146. 
Neutrophils may also induce leaky vasculature to support extravasation of disseminated 
cancer cells by expression of matrix metalloproteinase 9 (MMP9) and BV8128,129. BV8 is also 
directly involved in cancer cell migration and the recruitment of neutrophils28,128,129. Anti-
metastatic functions of neutrophils are mediated by H2O2 or thrombospondin 1 (TSP1), but 
the latter is degraded by neutrophil elastase (NE) and cathepsin G (CG) during 
inflammation133,160,163,164. ALOX5, arachidonate 5-lipoxygenase; ECM, extracellular matrix; 
TGFβ, transforming growth factor β. 
 
Table 1. Bidirectional communication between neutrophils and other immune cells in 
homeostasis and cancer 
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Factor(s) Source Responder Outcome Reference 
CXCL1, 2, 5, 8 Megakaryocyte 
Endothelial cell 
Cancer cell 
Neutrophil Neutrophil release 
from bone marrow in 
homeostasis and 
cancer; recruitment to 
tumors 
34,37,38,58,101,1
02,104,109-
111,139,140 
G-CSF Fibroblast 
Cancer cell 
Neutrophil Granulopoiesis in 
homeostasis and 
cancer; neutrophil 
polarization and 
immunosuppression 
15-17,25-
28,57,87,133,152,
156,178 
GM-CSF Cancer cell Neutrophil 
Monocyte 
Granulopoiesis in 
homeostasis and 
cancer; neutrophil 
polarization and 
immunosuppression 
24,29,30 
IL-1β Macrophage 
Dendritic cell 
CD4+ T cell 
γδ T cell 
IL-17 and G-CSF-
mediated 
granulopoiesis in 
homeostasis and 
cancer 
26,56,57,59-63 
IL-17 CD4+ T cell 
γδ T cell 
Fibroblast 
Bone marrow 
stromal cells 
G-CSF-mediated 
granulopoiesis in 
homeostasis and 
cancer 
26,46,48,57,121 
IL-23 Macrophage 
Dendritic cell 
CD4+ T cell 
γδ T cell 
IL-17 and G-CSF-
mediated 
granulopoiesis in 
homeostasis and 
cancer 
46 
iNOS, ARG1 Neutrophil T cells Suppression of anti- 26,130 
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Monocyte NK cell 
 
tumor immunity 
TGFβ Neutrophil 
Breg 
T cells 
NK cell 
Neutrophil 
Immunosuppression 
in tumor 
microenvironment 
and metastasis 
25,65,85,86,88 
TNF Endothelial cell 
Cancer cell 
CD4 T cell 
Neutrophil 
Endothelial cell 
IL-17 and G-CSF-
mediated 
granulopoiesis in 
homeostasis; 
neutrophil recruitment 
to tumors; MET 
upregulation in 
neutrophils 
57,121,134,148 
TPO Unknown Megakaryocyte 
 
CXCR2 ligand-
dependent release of 
neutrophils from bone 
marrow in 
homeostasis 
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[ARG1, arginase 1; CXCL, C-X-C ligand; G-CSF, granulocyte-colony stimulating factor; GM-
CSF, granulocyte-macrophage-colony stimulating factor; IL, interleukin; iNOS, inducible nitric 
oxide synthase; TGFβ, transforming growth factor β; TNF, tumour necrosis factor; TPO, 
thrombopoietin] 
 
Glossary 
 
αβ T cells 
Most CD4+ and CD8+ T cells are αβ T cells, in which the T cell receptor (TCR) is composed 
of a heterodimer of an α and a β chain. 
 
 γδ T cells 
A small subset of T cells whose TCR consists of a γ and a δ chain. These cells behave like 
innate immune cells and are largely divided into IL-17- and IFNγ-producing subsets. 
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Innate lymphoid cells 
Innate immune cells that belong to the lymphoid lineage, but lack antigen-specific receptors.  
 
Neutrophil polarization 
A state of neutrophil activation in response to specific cues from its environment, which can 
promote or limit disease progression.  
 
Th1/Th2 
Two major activation states of CD4+ T-helper cells expressing distinct cytokines and exerting 
different functions. In general, Th1 cells provide immunity against intracellular pathogens, 
whereas Th2 cells mediate immune responses against extracellular parasites. 
 
M1/M2 
Term for macrophage polarization states, where M1 and M2 represent opposing ends of the 
macrophage activation spectrum. Historically, M1 represents an anti-tumor activation state, 
whereas M2 macrophages are pro-tumoral; although, this restrictive nomenclature fails to 
represent tumor-associated macrophage biology.  
 
N1/N2 
Proposed binary classification to distinguish tumor-inhibiting (N1) from tumor-promoting (N2) 
neutrophils in the cancer setting. However, further evidence to define these polarization 
states and their relation to type 1/2 immunity is required before applying this terminology to 
cancer-associated neutrophils. 
 
Myeloid-derived suppressor cells  
A heterogeneous group of immunosuppressive myeloid cells including neutrophils that 
expand in cancer patients and mouse cancer models.  
 
Autochthonous model 
Models of cancer in which tumors arise spontaneously from genetic manipulation or injection 
of a carcinogen. 
 
Neutrophil extracellular traps 
Extracellular neutrophil-derived networks of DNA, fibers and various proteins such as 
elastase and histones. Release of NETs (NETosis) occurs in response to pathogen infection, 
sterile inflammation and cancer.  
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Pre-metastatic niche 
A microenvironment in secondary organs primed by the primary tumor that is populated by 
non-cancer cells that promote seeding of metastasizing cancer cells.  
 
Regulatory B cells 
A subpopulation of immunosuppressive B cells involved in immunological tolerance.  
 
Secretome 
The total secreted factors of a cell or tissue.  
 
 
 
 
 
 
Key points  
 
• In patients with solid cancers, neutrophils expand both in the tumor microenvironment 
and systemically, and are generally associated with a poor prognosis. 
• Genetically engineered mouse models for cancer have been crucial in identifying 
underlying mechanisms by which neutrophils influence tumor initiation, growth and 
metastasis.  
• Neutrophils exert multifaceted and sometimes opposing roles during cancer initiation, 
growth and dissemination  
• Primary tumors activate granulopoiesis in the bone marrow and actively stimulate the 
release and recruitment of both mature neutrophils and their progenitors. 
• Depending on the spectrum and quantity of soluble mediators produced by cancer 
cells and cancer-associated cells, neutrophils can be polarized into different 
activation states by which they elicit various pro- or anti-tumor functions.  
• Interactions between neutrophils and other (immune) cells are key in exerting their 
function, and the interaction networks observed in cancer are often highly reminiscent 
of those seen in other immunological diseases.  
• Neutrophils modulate the efficacy of cancer therapies, and can also serve as 
biomarkers for progression and therapy response in cancer patients.  
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• Now that there is a growing understanding of the impact of neutrophils on cancer, the 
mechanisms by which neutrophils promote cancer progression may be utilized as 
targets to maximize the efficacy of anti-cancer therapeutics.  
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